Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
insulin glargine
|
| gptkbp:activeDuring |
insulin glargine
|
| gptkbp:administrativeDivision |
once daily
|
| gptkbp:availableIn |
generic version
|
| gptkbp:clinicalTrials |
Phase III trials
blood sugar control basal insulin therapy recommended for Type 1 and Type 2 diabetes used in conjunction with rapid-acting insulin |
| gptkbp:contraindication |
hypersensitivity to insulin glargine
severe hypoglycemia |
| gptkbp:date |
2015-12-15
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
long-acting insulin
steady-state concentration achieved after 2 to 4 days |
| gptkbp:duration |
1 to 2 hours
up to 24 hours |
| gptkbp:formFactor |
injection
|
| gptkbp:formulation |
U-100 insulin
U-300 insulin |
| gptkbp:hasCapacity |
educational resources available
available patient assistance programs |
| gptkbp:hasPopulation |
children
adults |
| gptkbp:healthcare |
carry glucose source
monitor blood glucose levels recognize hypoglycemia symptoms |
| https://www.w3.org/2000/01/rdf-schema#label |
Basaglar
|
| gptkbp:interactsWith |
alcohol
ACE inhibitors beta-blockers thiazolidinediones |
| gptkbp:mandates |
Type 1 diabetes
Type 2 diabetes |
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by region
insurance coverage may apply |
| gptkbp:packaging |
pre-filled pen
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:relatedTo |
gptkb:Lantus
insulin |
| gptkbp:route |
subcutaneous
|
| gptkbp:safetyFeatures |
well-tolerated
|
| gptkbp:sideEffect |
weight gain
injection site reactions hypoglycemia |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:technologyArea |
subcutaneous injection
rotate injection sites |
| gptkbp:usedFor |
diabetes management
|